In this presentation, we will discuss how 3D bioprinting technologies enable the fabrication of more reliable tissue models, which have wide application, including the development and validation of the efficacy of pharmaceutical products, screening of drug therapies and understanding of tissue development and oncology processes.
A presentation by Cecilia Soto, Field Application Specialist at Cellink.
View of the Speaker
Question 1: What drives you?
There are many factors that drive my believe within CELLINK. To see how we can reach and support a variety of research groups, where each of them pushes the boundaries of science, is just fascinating. Personally, since my family had an unfortunate lost cancer case in the closest circle, I hope that especially cancer research reaches a state in which we can go from lost cases to “here is a personalized and curing treatment plan for you”.
Question 2: Why should the delegate attend your session?
To gain more insight in our 3D bioprinting technology and how 3D bioprinting can be included in other health care sectors, such as microfluidics.
Question 3: What emerging technologies / trends do you see as having the greatest potential in the short and long run?
The field of 3D bioprinting is increasingly growing with more researchers choosing to opt in for more physiologically relevant models. From high-throughput 3D bioprinting for drug development to patient-specific disease models in the context of personalized medicine – all of these will have a great impact in the short but also in a longer run. In time, new drugs and treatments can be developed following a process designed to minimize failures and reduce animal testing. Using bioprinted tissue can help researchers determine drug candidate’s efficacy sooner, enabling them to save money and time.
Question 4: What kind of impact do you expect them to have?
To create the future of health.
Question 5: What are the barriers that might stand in the way?
3D bioprinting has already made big strides being used in tissue engineering, development of disease, tumor and organ models as well as organ-on-a-Chip applications. However, the goal of organ printing and personalized treatments is still some way off and poses various challenges such as developing vascularization and automation among others. I believe those can be overcome by combining multiple technologies, whilst working hand in hand with biology. For example, in the fight against cancer, converging multiple technologies has the potential to help doctors customize treatment through omics-based tumor profiling, miniaturized drug delivery, and tissue replacement.
About CELLINK AB
CELLINK is creating the future of health as part of BICO, the world’s leading bioconvergence company. At the forefront of the bioprinting industry, CELLINK aims to alleviate organ donor shortage with biofabricated transplantable organs and remains committed to reducing our dependence on animal testing and increasing efficiencies in drug development with more physiologically relevant bioprinted organ models.
Cecilia Soto is speaker at the 2022 edition of the 3DBioPrinting Conference during the 3D Medical Printing Series